TherapeuticsMD, Inc. reported its financial results for the first quarter of 2026, revealing a net income of $95,000, a significant improvement from a net loss of $653,000 in the same period last year. The company generated $724,000 in license revenue, marking a 84% increase from $393,000 in the first quarter of 2025. This growth in revenue is attributed to increased sales of licensed products, particularly following the strategic shift to a pharmaceutical royalty company after the Mayne Transaction in December 2022.
Operating expenses for the quarter decreased to $1.447 million from $1.674 million in the prior year, primarily due to lower general and administrative costs and the absence of patent write-offs, which totaled $88,000 in the first quarter of 2025. General and administrative expenses fell by 9.3% to $1.353 million, reflecting reduced professional fees and share-based compensation costs. The company reported a loss from operations of $723,000, an improvement from the $1.281 million loss recorded in the same quarter of 2025.
In terms of operational metrics, TherapeuticsMD's cash and cash equivalents increased to $8.419 million as of March 31, 2026, compared to $7.483 million at the end of 2025. The company continues to maintain a minimal employee headcount, with only one full-time employee engaged in executive functions as part of its ongoing transition. The company has also engaged external consultants to support its operations and manage relationships with partners.
Looking ahead, TherapeuticsMD's outlook remains cautious as it navigates the complexities of its new business model. The company may need to raise additional capital to ensure liquidity and fund operations until it achieves cash flow positivity. The potential for future financing is contingent on market conditions and the performance of its licensed products. The company has also indicated that it is exploring various strategic alternatives, including potential mergers or asset sales, but has not set a timetable for these efforts. The ongoing litigation with Mayne Pharma regarding contractual disputes adds another layer of uncertainty to its financial outlook.
About TherapeuticsMD, Inc.
TherapeuticsMD is a pharmaceutical royalty company specializing in women’s health products. It owns or licenses rights to products like IMVEXXY, BIJUVA, and ANNOVERA, generating revenue through royalties from licensed pharmaceutical products sold worldwide. The company focuses on licensing, patent protection, and strategic partnerships, relying on third-party manufacturers and licensees to commercialize its portfolio in various global markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.